Illumina Appoints Daniel Skovronsky To Its Board
(RTTNews) - Illumina, Inc. (ILMN) announced on Tuesday the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026.
Skovronsky brings experience in drug discovery, clinical development, and translational medicine to the position. He currently serves as Chief Scientific and Product Officer at Eli Lilly and Company (LLY) and as President of Lilly Research Laboratories.
Previously, Skovronsky served as a board member of Myriad Genetics, Inc. He also founded Avid Radiopharmaceuticals in 2004 and served as its Chief Executive Officer.
ILMN closed Tuesday's trade at $164.93, up 2.20%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.